Last reviewed · How we verify
ISOPROTERENOL
Isoproterenol activates beta-adrenergic receptors without affecting alpha-adrenergic receptors.
Isoproterenol, a non-selective beta-adrenergic receptor agonist, is currently marketed for improving hemodynamic status in shock patients. Its key strength lies in its ability to activate beta-adrenergic receptors without affecting alpha-adrenergic receptors, which can be advantageous in certain clinical scenarios. The primary risk is the competition from epinephrine and albuterol, both of which offer additional benefits such as vasoconstriction and selective bronchodilation, respectively.
At a glance
| Generic name | ISOPROTERENOL |
|---|---|
| Also known as | isoprenaline |
| Drug class | Beta-adrenergic agonist |
| Target | beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1956 |
Mechanism of action
Isoproterenol is designed to strongly bind to and activate beta-adrenergic receptors, which are involved in various physiological responses such as heart rate and bronchodilation. It has minimal interaction with alpha-adrenergic receptors, making it more selective for beta-adrenergic effects.
Approved indications
- Improving hemodynamic status in shock
- Treatment of bronchospasm during anesthesia
Common side effects
- Tachycardia
- Palpitations
- Headache
- Dizziness
- Visual blurring
- Angina
- Ventricular arrhythmias
- Adams-Stokes attacks
- Pulmonary edema
- Dyspnea
- Sweating
- Mild tremors
Drug interactions
- Epinephrine
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
- Levothyroxine Sodium
- Chlorpheniramine
- Triprolidine
- Diphenhydramine
- Beta-adrenergic Blocking Drugs (e.g., Propranolol)
Key clinical trials
- Does Vitamin C Increase the Body Heat Generated By The Nervous System? (NA)
- Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences (PHASE4)
- General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Using Flow Diverter (NA)
- Early Neurovascular Adaptations in Aging Women (EARLY_PHASE1)
- Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
- Endothelial Dysfunction After SCI
- Autoimmune Basis for Postural Tachycardia Syndrome (NA)
- EXPORT Randomized Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISOPROTERENOL CI brief — competitive landscape report
- ISOPROTERENOL updates RSS · CI watch RSS